Artesunate combinations for treatment of malaria: meta-analysis

[1]  M. Fanning.  Review: artesunate added to standard drug treatment reduces treatment failure in malaria , 2004 .

[2]  P. Rosenthal,et al.  Sulfadoxine/pyrimethamine alone or with amodiaquine or artesunate for treatment of uncomplicated malaria: a longitudinal randomised trial , 2002, The Lancet.

[3]  F. Cobelens,et al.  For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .

[4]  P. Olliaro,et al.  Controlling malaria: challenges and solutions , 2001, Tropical medicine & international health : TM & IH.

[5]  R. Price,et al.  Drug resistant falciparum malaria: clinical consequences and strategies for prevention. , 2001, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[6]  C. Drakeley,et al.  Artesunate reduces but does not prevent posttreatment transmission of Plasmodium falciparum to Anopheles gambiae. , 2001, The Journal of infectious diseases.

[7]  Richard N. Price,et al.  Effects of artesunate-mefloquine combination on incidence of Plasmodium falciparum malaria and mefloquine resistance in western Thailand: a prospective study , 2000, The Lancet.

[8]  K. Bojang,et al.  Efficacy of artesunate plus pyrimethamine-sulphadoxine for uncomplicated malaria in Gambian children: a double-blind, randomised, controlled trial , 2000, The Lancet.

[9]  P. Olliaro,et al.  Averting a malaria disaster , 1999, The Lancet.

[10]  N. White,et al.  Antimalarial drug resistance and combination chemotherapy. , 1999, Philosophical transactions of the Royal Society of London. Series B, Biological sciences.

[11]  G. Snounou,et al.  The use of PCR genotyping in the assessment of recrudescence or reinfection after antimalarial drug treatment. , 1998, Parasitology today.

[12]  E. Lagarde,et al.  Impact of chloroquine resistance on malaria mortality. , 1998, Comptes rendus de l'Academie des sciences. Serie III, Sciences de la vie.

[13]  Christopher H Schmid,et al.  Summing up evidence: one answer is not always enough , 1998, The Lancet.

[14]  N. White,et al.  Assessment of the pharmacodynamic properties of antimalarial drugs in vivo , 1997, Antimicrobial agents and chemotherapy.

[15]  R. Price,et al.  Effects of artemisinin derivatives on malaria transmissibility , 1996, The Lancet.

[16]  L. Stewart,et al.  Practical methodology of meta-analyses (overviews) using updated individual patient data. Cochrane Working Group. , 1995, Statistics in medicine.

[17]  R. Price,et al.  Artesunate versus artemether in combination with mefloquine for the treatment of multidrug-resistant falciparum malaria. , 1995, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[18]  N. White,et al.  Treatment of multidrug-resistant Plasmodium falciparum malaria with 3-day artesunate-mefloquine combination. , 1994, The Journal of infectious diseases.

[19]  D L Demets,et al.  Methods for combining randomized clinical trials: strengths and limitations. , 1987, Statistics in medicine.

[20]  R Peto,et al.  Why do we need systematic overviews of randomized trials? , 1987, Statistics in medicine.

[21]  W. Haenszel,et al.  Statistical aspects of the analysis of data from retrospective studies of disease. , 1959, Journal of the National Cancer Institute.

[22]  J. Breman,et al.  The intolerable burden of malaria: a new look at the numbers. , 2001, The American journal of tropical medicine and hygiene.

[23]  R. Snow,et al.  Estimating mortality, morbidity and disability due to malaria among Africa's non-pregnant population. , 1999, Bulletin of the World Health Organization.

[24]  Stephen J. Sharp,et al.  Meta-analysis regression , 1998 .